Semaglutide
The assignment that kept growing
From a longer-lasting GLP-1 signal to diabetes, weight management and further uses.
Journey published October 11, 2026 · Evidence reviewed 2026-10-11
- 01Before I had a nameLaboratory work · Reported 2015
- 02The animal roomPreclinical pharmacology and safety
- 03The first human questionsEarly clinical research · Published 2015–2018
- 04The diabetes assignmentSUSTAIN and first US approvals · 2016–2019
- 05The assignment gets biggerObesity, heart and kidney research · 2018–2025
- 06More doors, more questionsOctober 2026 combination, observational and kidney reports
The US story includes diabetes, weight management and selected heart, kidney and liver indications. Each belongs to a specific product and population. Separately, on October 15, 2026, Europe’s CHMP recommended changing the indication for Kyinsu, the insulin icodec–semaglutide combination; the European Commission decision remained pending in the notice reviewed October 17. On October 20, Novo Nordisk also reported exploratory post hoc women’s analyses of REDEFINE 1; those results concern investigational CagriSema, not semaglutide alone or a new approval.
Open the medicine’s evidence profile · Other journeys
Documented milestones, not every unpublished experiment. The story is fictional; each chapter identifies the real study population and source.